A$4.18 Artrya Limited (AYA.AX) ASX pre-market 15 Jan 2026: 59.57% model upside
The AYA.AX stock opens pre-market at A$4.18, down 6.28% from yesterday as traders digest valuation and AI adoption signals. Artrya Limited (AYA.AX) on the ASX uses AI for coronary disease detection with its Salix platform. We provide a focused AYA.AX stock analysis, linking price drivers, technical signals and Meyka AI forecast for investors watching AI healthcare names.
AYA.AX stock: pre-market price, volume and recent moves
AYA.AX stock is trading at A$4.18 with a one-day change of -6.28% and volume at 865,338. The stock opened at A$4.22 and hit an intraday low of A$4.00 and high of A$4.34. The 50-day average is A$3.84 and the 200-day average is A$2.04, showing medium and longer term support levels.
Financials and valuation for AYA.AX stock
Artrya reports an EPS of -0.18 and a trailing PE of -23.56, reflecting current losses. Market capitalisation stands at A$480,476,800 with 113,320,000 shares outstanding. Key ratios show a high P/B of 20.52 and price-to-sales near 17,159.89, which signals premium pricing versus revenue. The current ratio is 8.27, and cash per share is 0.11.
Technicals and trading signals for AYA.AX stock
Momentum is strong but stretched: RSI is 70.89 and MFI is 82.92, both in overbought territory. MACD is positive with MACD 0.40 and signal 0.32. Bollinger bands centre at A$4.20 with upper band A$5.17 and lower band A$3.23. Average volume is 905,953, so current activity is near normal levels.
Growth drivers and AI product outlook for AYA.AX stock
Artrya’s Salix product targets coronary CT automation, giving it a clear AI growth story in healthcare. R&D intensity is high with R&D to revenue around 197.5%, indicating product development focus. Recent adoption catalysts would be regulatory approvals and hospital contracts, which directly affect recurring cloud revenue and valuation multiples.
Risks, liquidity and sector context for AYA.AX stock
AYA.AX stock sits in Healthcare information services, a sector with average P/E near 35.15. Primary risks include negative earnings, thin revenue base, and high R&D costs. Liquidity is reasonable with Avg Volume 905,953, but volatility is high: one-year return is 523.53%, highlighting episodic moves. Balance sheet risk is low given debt to equity 0.03.
Meyka Grade and forecast for AYA.AX stock
Meyka AI rates AYA.AX with a score out of 100: 59.22 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects yearly A$6.67, which implies +59.57% vs the current A$4.18. Forecasts are model-based projections and not guarantees.
Final Thoughts
Key takeaway: AYA.AX stock trades at A$4.18 on 15 Jan 2026 with stretched technicals and a growth story tied to its Salix AI product. Valuation metrics are rich versus current revenue, with P/B 20.52 and price-to-sales extreme. Meyka AI’s forecast model projects A$6.67 in 12 months, an implied upside of 59.57% from today’s price. That projection assumes steady product traction, regulatory progress and contract wins. Counterweights include negative EPS, high R&D spend and episodic volatility. For AI-focused investors the case is growth at a premium. For value-focused investors, current multiples demand visible revenue scale. Forecasts are model-based projections and not guarantees. Use this AYA.AX stock analysis with other research and risk controls.
FAQs
What drives the AYA.AX stock price today?
Today the AYA.AX stock price moves on earnings outlook, product adoption signals for Salix, and technical selling. Key visible drivers are EPS -0.18, intraday volume 865,338, and market reaction to valuation metrics.
What is Meyka AI’s view on AYA.AX stock?
Meyka AI rates AYA.AX C+ with a score 59.22 and a HOLD suggestion. The model projects A$6.67 yearly, implying +59.57%, but notes forecasts are projections and not guarantees.
Are there clear valuation concerns for AYA.AX stock?
Yes. Valuation shows P/B 20.52 and price-to-sales near 17,159.89, which exceed typical healthcare peers. Those metrics reflect low current revenue and high investor expectations.
When are Artrya’s next earnings or announcements relevant to AYA.AX stock?
Artrya’s next earnings announcement is scheduled for 24 Feb 2026. Material contract wins or regulatory updates ahead of that date could move the AYA.AX stock significantly.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
